Avacta Cuts Convertible Debt with New Share Issue on AIM

Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.

Avacta Group plc, a clinical-stage biopharmaceutical company specializing in tumor-activated oncology therapies through its proprietary pre|CISION platform, is developing peptide drug conjugates intended to deliver potent cancer drugs directly to tumors while limiting damage to healthy tissue. Its pipeline includes AVA6000, a FAP-enabled version of doxorubicin showing early activity in certain tumor types, and AVA6103, a sustained-release candidate in a Phase 1 trial for hard-to-treat cancers.

The company has issued and allotted 1,604,063 new ordinary shares to settle the conversion of £1.20 million of its unsecured convertible bond, reducing the remaining bond principal to £19.20 million. Following admission of these shares to trading on AIM, Avacta’s issued share capital will rise to 457,892,574 ordinary shares, slightly diluting existing shareholders but modestly strengthening the balance sheet by lowering outstanding debt and clarifying the company’s capital structure.

Spark’s Take on AVCT Stock

According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.

Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on AVCT stock, click here.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biopharmaceutical and life sciences company focused on oncology, developing its proprietary pre|CISION platform to expand the reach of highly potent cancer therapies. Its pre|CISION peptide drug conjugates are designed to deliver cytotoxic payloads selectively to tumors via fibroblast activation protein, aiming to improve efficacy while reducing systemic toxicity.

The company’s lead program, faridoxorubicin (AVA6000), is a FAP-enabled version of doxorubicin targeting tumor microenvironments and has shown preliminary activity in salivary gland cancer and soft tissue sarcoma. A second candidate, AVA6103, uses a sustained-release mechanism to maintain high intratumoral drug levels with limited systemic exposure and is being evaluated in the Phase 1 FOCUS-01 trial for cancers with unmet needs.

Average Trading Volume: 2,171,986

Technical Sentiment Signal: Buy

Current Market Cap: £360.9M

For an in-depth examination of AVCT stock, go to TipRanks’ Overview page.